title: 6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist.
abstract: Previous experiments with the mouse vas deferens have shown that cannabidiol produces surmountable antagonism of cannabinoid CB(1) receptor agonists at concentrations well below those at which it binds to cannabinoid CB(1) receptors and antagonizes alpha(1)-adrenoceptor agonists insurmountably. It also enhances electrically evoked contractions of this tissue. We have now found that subtle changes in the structure of cannabidiol markedly influence its ability to produce each of these effects, suggesting the presence of specific pharmacological targets for this non-psychoactive cannabinoid. Our experiments were performed with cannabidiol, 6"-azidohex-2"-yne-cannabidiol, abnormal-cannabidiol and 2'-monomethoxy- and 2',6'-dimethoxy-cannabidiol. Of these, 6"-azidohex-2"-yne-cannabidiol was as potent as cannabidiol in producing surmountable antagonism of (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone (R-(+)-WIN55212) in vasa deferentia. However, it produced this antagonism with a potency that matched its cannabinoid CB(1) receptor affinity, suggesting that, unlike cannabidiol, it is a competitive cannabinoid CB(1) receptor antagonist. Moreover, since it did not enhance the amplitude of electrically evoked contractions, it may be a neutral cannabinoid CB(1) receptor antagonist.
authors.affiliation: Department of Biomedical Sciences, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.
authors.forename: Adèle
authors.initials: A
authors.lastname: Thomas
authors.forename: Ruth A
authors.initials: RA
authors.lastname: Ross
authors.forename: Bijali
authors.initials: B
authors.lastname: Saha
authors.forename: Anu
authors.initials: A
authors.lastname: Mahadevan
authors.forename: Raj K
authors.initials: RK
authors.lastname: Razdan
authors.forename: Roger G
authors.initials: RG
authors.lastname: Pertwee
mesh_terms: D000255:Adenosine Triphosphate / Q000031:analogs & derivatives* / Q000494:pharmacology; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects; D001923:Brain Chemistry / Q000187:drug effects; D002185:Cannabidiol / Q000031:analogs & derivatives* / Q000494:pharmacology*; D003511:Cyclohexanols / Q000494:pharmacology; D004558:Electric Stimulation; D066298:In Vitro Techniques; D008297:Male; D008566:Membranes / Q000187:drug effects; D051379:Mice; D010656:Phenylephrine / Q000494:pharmacology; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors*; D014649:Vas Deferens / Q000187:drug effects
chemical_list: C493219:6''-azidohex-2''-yne-cannabidiol; D000316:Adrenergic alpha-Agonists; D003511:Cyclohexanols; D043884:Receptor, Cannabinoid, CB1; D002185:Cannabidiol; D010656:Phenylephrine; C005147:5'-adenylyl (beta,gamma-methylene)diphosphonate; C054649:3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol; D000255:Adenosine Triphosphate